Petrelintide (development name ZP8396)[1] is an amylin analogue dosed once weekly, developed by Zealand Pharma for the treatment of type 2 diabetes and obesity.
[2][3][4] Preclinical data suggests it may be more effective in combination with semaglutide.
[5] In June 2024 the company announced results for a Phase 1b trial, which found 8.6 percent weight loss over 16 weeks.
[6]